Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Harnessing Natural Killer Cells in Non-Small Cell Lung Cancer
Éilis Russell, Melissa J. Conroy, Martin P. Barr
Cells (2022) Vol. 11, Iss. 4, pp. 605-605
Open Access | Times Cited: 21

Showing 21 citing articles:

Natural killer cell homing and trafficking in tissues and tumors: from biology to application
Guanghe Ran, Yu qing Lin, Lei Tian, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 140
Liquid biopsy techniques and lung cancer: diagnosis, monitoring and evaluation
Fei Ren, Qian Fei, Kun Qiu, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 27
The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer
Fortunato Ciardiello, Fred R. Hirsch, Robert Pirker, et al.
Cancer Treatment Reviews (2023) Vol. 122, pp. 102664-102664
Open Access | Times Cited: 24
Metabolic reprogramming and immune evasion: the interplay in the tumor microenvironment
Haixia Zhang, Shizhen Li, Dan Wang, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 9
Discovery of novel dual tubulin and MMPs inhibitors for the treatment of lung cancer and overcoming drug resistance
Guimei Li, Meng Wang, Li Luo, et al.
European Journal of Medicinal Chemistry (2025) Vol. 285, pp. 117249-117249
Closed Access
Identification of prognostic biomarker of non-small cell lung cancer based on mitochondrial permeability transition-driven necrosis-related genes and determination of anti-tumor effect of ARL14
Zhifei Ma, Wen Chen, Aiping Zhang, et al.
Hereditas (2025) Vol. 162, Iss. 1
Open Access
Brigatinib can inhibit proliferation and induce apoptosis of human immortalized keratinocyte cells
Qi Yang, Dan Zhao, Linjie Ju, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Adopting tomorrow’s therapies today: a perspective review of adoptive cell therapy in lung cancer
Faith Abodunrin, Daniel J. Olson, Oluwatosin Emehinola, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Immunomodulatory role of metalloproteinase ADAM17 in tumor development
Kai Wang, Zixue Xuan, Xiaoyan Liu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 25
Unravelling the role of tumor microenvironment responsive nanobiomaterials in spatiotemporal controlled drug delivery for lung cancer therapy
Dadi A. Srinivasarao, Saurabh Shah, Paras Famta, et al.
Drug Delivery and Translational Research (2024) Vol. 15, Iss. 2, pp. 407-435
Closed Access | Times Cited: 3
EGFR Inhibition Strongly Modulates the Tumour Immune Microenvironment in EGFR-Driven Non-Small-Cell Lung Cancer
Carolin Selenz, Anik Compes, Marieke Nill, et al.
Cancers (2022) Vol. 14, Iss. 16, pp. 3943-3943
Open Access | Times Cited: 17
Harnessing Natural Killer Cells for Lung Cancer Therapy
Shoubao Ma, Michael A. Caligiuri, Jianhua Yu
Cancer Research (2023) Vol. 83, Iss. 20, pp. 3327-3339
Closed Access | Times Cited: 9
Dynamic immune signatures of patients with advanced non–small-cell lung cancer for infection prediction after immunotherapy
Yung‐Hung Luo, Chia‐I Shen, Chi‐Lu Chiang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Identification of natural killer cell associated subtyping and gene signature to predict prognosis and drug sensitivity of lung adenocarcinoma
Dexin Zhang, Yujie Zhao
Frontiers in Genetics (2023) Vol. 14
Open Access | Times Cited: 5
In-silico design, pharmacophore-based screening, and molecular docking studies reveal that benzimidazole-1,2,3-triazole hybrids as novel EGFR inhibitors targeting lung cancer
Sunil Kumar, Iqra Ali, Faheem Abbas, et al.
Journal of Biomolecular Structure and Dynamics (2023) Vol. 42, Iss. 18, pp. 9416-9438
Closed Access | Times Cited: 5
Unveiling the impact of cell death-related genes and immune dynamics on drug resistance in lung adenocarcinoma: a risk score model and functional insights
Yuanyuan Xiao, Shancheng He, Baochang Xie, et al.
Discover Oncology (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 1
The mechanism of Bai He Gu Jin Tang against non-small cell lung cancer revealed by network pharmacology and molecular docking
Ruifei Xie, Ziyu Song, Lu-yao Xu-shao, et al.
Medicine (2022) Vol. 101, Iss. 52, pp. e32555-e32555
Open Access | Times Cited: 8
AURKA Identified as Potential Lung Cancer Marker through Comprehensive Bioinformatic Analysis and Experimental Verification
Shan Shi, Y. Qiu, Zhongwen Jin, et al.
Critical Reviews in Eukaryotic Gene Expression (2023) Vol. 33, Iss. 5, pp. 39-59
Closed Access | Times Cited: 4
Augmenting Granzyme B–Expressing NK Cells by Invariant NKT Ligand–Loaded APCs in Patients with Postoperative Early Stage Non–Small Cell Lung Cancer: Results of a Randomized Phase II Study
Tomonori Iyoda, Kanako Shimizu, Masami Kawamura, et al.
ImmunoHorizons (2023) Vol. 7, Iss. 1, pp. 1-16
Open Access | Times Cited: 3
Multi-omics sequencing revealed endostar combined with cisplatin treated non small cell lung cancer via anti-angiogenesis
Yufei Wang, Hong Ren
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access
Research Progress on the Potential Role of NK Cells in Various Tumors
勇鑫 傅
Advances in Clinical Medicine (2023) Vol. 13, Iss. 05, pp. 8749-8755
Closed Access
Page 1

Scroll to top